Sensei Biotherapeutics (NASDAQ:FTH) Stock Price Up 7.1% – Here’s Why

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) shares were up 7.1% during mid-day trading on Tuesday. The stock traded as high as $28.00 and last traded at $29.0210. 55,706 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 238,846 shares. The stock had previously closed at $27.10.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Needham & Company LLC initiated coverage on Sensei Biotherapeutics in a research report on Friday, August 21st. They set a “buy” rating and a $56.00 price objective for the company. Oppenheimer initiated coverage on Sensei Biotherapeutics in a report on Tuesday, July 28th. They set an “outperform” rating and a $60.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Monday, September 14th. BTIG Research reissued a “buy” rating and issued a $55.00 target price on shares of Sensei Biotherapeutics in a research report on Thursday, July 16th. Finally, JonesTrading initiated coverage on Sensei Biotherapeutics in a report on Tuesday, August 4th. They set a “buy” rating and a $55.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $56.25.

Sensei Biotherapeutics Trading Up 5.1%

The company’s 50 day moving average is $32.04. The stock has a market cap of $735.79 million, a P/E ratio of -0.20 and a beta of -0.29.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($5.04) by $2.20. As a group, research analysts predict that Sensei Biotherapeutics, Inc. will post -13.69 earnings per share for the current fiscal year.

Institutional Trading of Sensei Biotherapeutics

Institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC purchased a new position in Sensei Biotherapeutics during the 2nd quarter worth approximately $307,000. Alyeska Investment Group L.P. acquired a new stake in Sensei Biotherapeutics during the 2nd quarter worth approximately $3,610,000. Vivo Capital LLC acquired a new stake in Sensei Biotherapeutics in the first quarter valued at approximately $22,758,000. Bank of America Corp DE boosted its holdings in shares of Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares in the last quarter. Finally, Stempoint Capital LP purchased a new stake in Sensei Biotherapeutics in the 1st quarter valued at $4,188,000. 10.50% of the stock is currently owned by institutional investors and hedge funds.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments.

Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.